Metabolic syndrome: therapeutic considerations.
1Center for Human Nutrition and Department of Clinical Nutrition, University of Texas Southwestern Medical Center at Dallas, TX 75390-9052, USA. scott.grundy@utsouthwestern.edu
Handbook of Experimental Pharmacology
|April 7, 2006
Summary
Metabolic syndrome increases risks for cardiovascular disease and type 2 diabetes. Management involves lifestyle changes and targeted drug therapies to address risk factors like high blood pressure and abnormal cholesterol.
Area of Science:
- Cardiology
- Endocrinology
- Metabolic Health
Background:
- Metabolic syndrome is a cluster of risk factors for atherosclerotic cardiovascular disease (ASCVD).
- Key components include atherogenic dyslipidemia, elevated blood pressure, hyperglycemia, prothrombotic, and proinflammatory states.
- Underlying factors include obesity, insulin resistance, inactivity, age, and hormonal influences.
Purpose of the Study:
- To outline the risks associated with metabolic syndrome.
- To discuss clinical management strategies for metabolic syndrome.
- To highlight therapeutic approaches for associated cardiovascular and diabetic risks.
Main Methods:
- Review of metabolic syndrome components and risk factors.
- Discussion of therapeutic lifestyle changes (TLCs).
- Overview of pharmacologic interventions for specific risk factors.
Main Results:
- Therapeutic lifestyle changes (weight loss, exercise, diet) improve multiple metabolic risk factors.
- Drug therapies are available for hypertension and dyslipidemia (targeting apo B, HDL).
- Glucose-lowering agents and aspirin may be indicated for specific high-risk individuals.
Conclusions:
- Metabolic syndrome necessitates clinical management to mitigate ASCVD and type 2 diabetes risks.
- Lifestyle modifications are the cornerstone of initial treatment.
- Pharmacological interventions are essential for managing specific, persistent risk factors.
Related Concept Videos
01:24Overview of Lipid Metabolism
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.